Peroxisome Proliferator-Activated Receptor Pathway Gene Polymorphism Associated With Extent of Coronary Artery Disease in Patients With Type 2 Diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial
- 27 September 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 124 (13), 1426-1434
- https://doi.org/10.1161/CIRCULATIONAHA.111.029173
Abstract
Coronary artery disease (CAD) is the major cause of death in patients with type 2 diabetes mellitus. Although demographic and clinical factors associated with extent of CAD in patients with diabetes mellitus have been described, genetic factors have not. We hypothesized that genetic variation in peroxisome proliferator-activated receptor (PPAR) pathway genes, important in diabetes mellitus and atherosclerosis, would be associated with extent of CAD in patients with diabetes mellitus. We genotyped 1043 patients (702 white, 175 blacks) from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) genetic cohort for 3351 variants in 223 PPAR pathway genes using a custom targeted-genotyping array. Angiographic end points were determined by a core laboratory. In whites, a single variant (rs1503298) in TLL1 was significantly ( P =5.5×10 −6 ) associated with extent of CAD, defined as number of lesions with percent diameter stenosis ≥20%, after stringent Bonferroni correction for all 3351 single nucleotide polymorphisms. This association was validated in the diabetic subgroups of 2 independent cohorts, the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH) post–myocardial infarction registry and the prospective Family Heart Study (FHS) of individuals at risk for CAD. TLL1 rs1503298 was also significantly associated with extent of severe CAD (≥70% diameter stenosis; P =3.7×10 −2 ) and myocardial jeopardy index ( P =8.7×10 −4 ). In general linear regression modeling, TLL1 rs1503298 explained more variance of extent of CAD than the previously determined clinical factors. We identified a variant in a single PPAR pathway gene, TLL1 , that is associated with the extent of CAD independently of clinical predictors, specifically in patients with type 2 diabetes mellitus and CAD. URL: http://www.clinicaltrials.gov . Unique identifier: NCT00006305.Keywords
This publication has 42 references indexed in Scilit:
- Baseline Coronary Angiographic Findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial (BARI 2D)The American Journal of Cardiology, 2009
- Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarctionNature, 2008
- Vascular CalcificationCell Metabolism, 2008
- The PPAR trio: Regulators of myocardial energy metabolism in health and diseaseJournal of Molecular and Cellular Cardiology, 2008
- Pioglitazone Can Downregulate Bone Morphogenetic Protein-2 Expression Induced by High Glucose in Human Umbilical Vein Endothelial CellsPharmacology, 2008
- Peroxisome proliferator‐activated receptors – from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular diseaseJournal of Internal Medicine, 2007
- The Final 10-Year Follow-Up Results From the BARI Randomized TrialJournal of the American College of Cardiology, 2007
- Bone Morphogenetic Protein-2 Induces Proinflammatory Endothelial PhenotypeThe American Journal of Pathology, 2006
- Selecting a Maximally Informative Set of Single-Nucleotide Polymorphisms for Association Analyses Using Linkage DisequilibriumAmerican Journal of Human Genetics, 2004
- Bone morphogenetic protein expression in human atherosclerotic lesions.JCI Insight, 1993